Updated guidelines for the management of Parkinson's disease

被引：17

作者：

Bhatia, K

Brooks, DJ ^{[1
]}

Burn, DJ

Clarke, CE

Grosset, DG

MacMahon, DG

Playfer, J

Schapira, AHV

Stewart, D

Widliams, AC

机构：

[1] Hammersmith Hosp, Imperial Coll Sch Med, London W12 0NN, England

[2] Univ London, Dept Clin Neurol, Inst Neurol, London, England

[3] Newcastle Gen Hosp, Dept Neurol, Reg Neurosci Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England

[4] City Hosp NHS Trust, Dept Neurol, Birmingham, W Midlands, England

[5] Univ Birmingham, Birmingham, W Midlands, England

[6] So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland

[7] Univ Plymouth, Plymouth PL4 8AA, Devon, England

[8] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[9] UCL, Dept Clin Neurosci, Royal Free & Univ Coll Med Sch, London, England

[10] Victoria Infirm, Glasgow G42 9TY, Lanark, Scotland

[11] Queen Elizabeth Hosp, Dept Neurosci, Birmingham B15 2TH, W Midlands, England

来源：

HOSPITAL MEDICINE | 2001年 / 62卷 / 08期

关键词：

D O I：

10.12968/hosp.2001.62.8.1621

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

New data on diagnosis, drug therapy, surgery and psychosocial concerns have emerged since the publication of the 1998 Guidelines for the Management of Parkinson's Disease. This article reviews new data and addresses issues left unanswered in the previous guidelines.

引用

页码：456 / 470

页数：15

共 126 条

[91] Selegiline delays the onset of disability in de novo parkinsonian patients [J].

Pålhagen, S ;

Heinonen, EH ;

Hägglund, J ;

Kaugesaar, T ;

Kontants, H ;

Mäki-Ikola, O ;

Palm, R ;

Turunen, J .

NEUROLOGY, 1998, 51 (02) :520-525

[92]

*PARK DIS SOC, 1999, PARK AW PRIM CAR GUI, P1

[93]

PARKINSON SG, 1989, ARCH NEUROL-CHICAGO, V46, P1052, DOI DOI 10.1001/archneur.1989.00520460028009

[94]

Parkinson Study Group, 2000, JAMA, V284, P1931

[95] Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study [J].

Pinter, MM ;

Pogarell, O ;

Oertel, WH .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (04) :436-441

[96] Sleep attacks in Parkinson's disease [J].

Pirker, W ;

Happe, S .

LANCET, 2000, 356 (9229) :597-598

[97] SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa [J].

Przuntek, T ;

Conrad, B ;

Dichgans, J ;

Kraus, PH ;

Krauseneck, P ;

Pergande, G ;

Rinne, U ;

Schimrigk, K ;

Schnitker, J ;

Vogel, HP .

EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 (02) :141-150

[98] A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa [J].

Rascol, O ;

Brooks, DJ ;

Korczyn, AD ;

De Deyn, PP ;

Clarke, CE ;

Lang, AE .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1484-1491

[99]

Reichmann H, 2000, J NEUROL, V247, P40

[100] Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease [J].

Richard, IH ;

Kurlan, R ;

Tanner, C ;

Factor, S ;

Hubble, J ;

Suchowersky, O ;

Waters, C ;

Goetz, C ;

Juncos, JL ;

Stern, M ;

Harrison, MB ;

Sethi, KD ;

Standaert, D ;

Trosch, R ;

Reich, S ;

Kieburtz, K ;

Feigin, A ;

Marshall, FJ ;

Gauthier, S ;

Panisset, M ;

Lew, ME ;

Friedman, JH ;

Paulson, G ;

Rodnitzky, RL ;

Hauser, R ;

Kurth, M ;

Hurtig, H ;

Thal, L ;

Elmer, LW ;

Perlmutter, JS ;

Golbe, LI ;

Comella, C ;

Lang, A ;

Mark, MH ;

Singer, C ;

Shoulson, I ;

Weiner, WJ ;

Pfeiffer, R ;

Marek, KL ;

Nutt, J ;

Wooten, GF ;

Jankovic, J ;

LeWitt, P ;

Hoehn, M ;

Bennett, J ;

Parsa, M ;

Koller, W .

NEUROLOGY, 1997, 48 (04) :1070-1077

← 4 5 6 7 8 9 10 11 12 13 →